Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

China Clears Wuyi Drug Combining Herb Extracts, Pharmaceutical (China)

This article was originally published in PharmAsia News

Executive Summary

China gave clearance to Wuyi International Pharmaceutical to market as early as January its new type of drug for treating hyperlipidemia. The company's CEO said the drug, Perilla Oil Capsule, includes extracts from Chinese herbs and reduces the length of treatment, compared with Western drugs. Lin Ou Wen said the company expects nearly U.S.$13 million in sales revenue next year. (Click here for more

Table

View full table

Tags:
Latest Headlines

Sweden's InDex To Stay Afloat Thanks To Mystery Merger Partner

China Biotech Podcast: AACR, BIOSECURE European Perspectives

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

See All
UsernamePublicRestriction

Register

SC065947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By